VENUS MEDTECH-B (02500) announced its financial results for the year ended December 31, 2025. The group recorded revenue of 307 million yuan, a decrease of 34.8% compared to the previous year. The loss attributable to owners of the parent company was 408 million yuan, representing a narrowing of 42.9% year-on-year. The basic loss per share was 0.93 yuan.

According to the announcement, all revenue for the reporting period was generated from the sale of medical devices. The company's revenue is primarily derived from six TAVR products currently marketed domestically and internationally: VenusA-Valve, VenusA-Plus, VenusA-Pro, VenusA-Deluxe, Venus-PowerX, and Venus-Vitae. These products are expected to continue to be a significant part of future sales.

The TPVR product, VenusP-Valve, received EU CE MDR certification on April 8, 2022, and was approved for market launch by the NMPA on July 11, 2022. Since its commercialization, it has become a major contributor to the company's overseas revenue.

The fluctuation in revenue was attributed to a decline in both product unit price and sales volume, a result of the intensely competitive market environment in China.